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Summary. Background and Objective. The plasminogen activator inhibitor type-1 (PAI-1) gene 
promoter contains 675 (4G/5G) polymorphism. The aim of this study was evaluate the effect of the 
PAI-1 promoter-675 (4G/5G) polymorphism on the concentrations of PAI-1 and tissue plasmino-
gen activator/PAI-1 (t-PA/PAI-1) complex and bleeding volume after on-pump cardiac surgery.
Material and Methods. A total of 90 patients were included in the study at Pauls Stradins Clini-
cal University Hospital. Seven patients were excluded due to surgical bleeding. Eighty-three patients 
were classified according to the PAI-1 genotype: 21 patients had the 4G/4G genotype; 42, the 
4G/5G genotype; and 20, the 5G/5G genotype. The following fibrinolysis parameters were re-
corded: the PAI-1 level preoperatively, D-dimer level at 0, 6, and 24 hours after surgery, and t-PA/
PAI-1 complex level 24 hours postoperatively. A postoperative bleeding volume was registered in 
mL 24 hours after surgery.
Results. The patients with the 5G/5G genotype had significantly lower preoperative PAI-1 lev-
els (17 [SD, 10.8] vs. 24 ng/mL [SD, 9.6], P=0.04), higher D-dimer levels at 6 hours (371 [SD, 
226] vs. 232 ng/mL [SD, 185], P=0.03) and 24 hours (326 [SD, 207] vs. 209 ng/mL  [SD, 160], 
P=0.04), and greater postoperative blood loss (568 [SD, 192] vs. 432 mL [168], P=0.02) compared 
with the 4G/4G carriers. There were no significant differences in the levels of the t-PA/PAI-1 com-
plex comparing different genotype groups. 
Conclusions. The carriers of the 5G/5G genotype showed the lower preoperative PAI-1 levels, 
greater chest tube blood loss, and higher D-dimer levels indicating that the 5G/5G carriers may 
have enhanced fibrinolysis.
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Introduction
Alterations in hemostasis during and after car-
diac surgery may have a diversity of etiologies in-
cluding surgery per se as well as effects of the car-
diopulmonary bypass (CPB) on the coagulation and 
the inflammation cascades, and their cross-reactions 
with the fibrinolytic and the kinin-kallikrein sys-
tems (1, 2). The balance among bleeding, normal 
hemostasis, and thrombosis is markedly influenced 
by the aggregation of functioning platelets, the rate 
of thrombin formation (3), and the fibrinolytic sys-
tem, which plays a determinant role in this pro-
cess (4, 5). Additionally, genetic predisposition in 
the physiopathology of bleeding may influence the 
body’s response to CPB (5–8).
The effects of the fibrinolytic system are medi-
ated by the activation of plasminogen to fibrin-de-
grading protease plasmin, which then lyses fibrin. 
Fibrinolytic activity depends on the balance between 
plasminogen activators and plasminogen activator 
inhibitors (9). The known plasminogen activators 
in the vascular system include tissue plasminogen 
activator (t-PA) and urinary type plasminogen ac-
tivator (u-PA), while the most important inhibitor 
is plasminogen activator inhibitor type 1 (PAI-1), a 
fast acting inhibitor of both t-PA and u-PA (6, 10).
The serine protease inhibitor PAI-1 is a linear 
glycoprotein with a molecular weight of 48 kDa 
(11). The active form is synthesized in platelets as 
well as in endothelium and adipose tissues. PAI-1 
binds rapidly to t-PA at a ratio of 1:1 forming a sta-
ble complex, which is cleared from circulation by 
macrophages lining the walls of the liver sinusoids. 
The formation of t-PA/PAI-1 complexes depends 
on the function and plasma concentrations of the 2 
proteins: the greater t-PA and PAI-1 concentrations 
are, the higher concentration of the complex will 
appear in the circulation (12). 
The plasma levels of PAI-1 are highly variable 
and are influenced by environmental and genetic 
factors (13). The human PAI-1 gene is located on 
chromosome 7, and it contains 9 exons and 8 introns 
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(14). The functional insertion/deletion (4G/5G) 
polymorphism has been described in the promoter 
region at position 675 of the PAI-1 gene (15). The 
4G/4G genotype is associated with the basal PAI-1 
levels greater by approximately 25%–30%, there-
fore, with a greater inhibition of fibrinolysis, and 
the 5G allele is associated with the lower levels of 
PAI-1 that could suggest a greater fibrinolytic ac-
tivity (16, 17). Recently researchers have reported 
systemic or topical applications of extended half-life 
PAI-1 in experimental animals to reduce the total 
blood loss in cases of PAI-1 deficiency (18).
The aim of this study was to investigate the effect 
of the PAI-1 promoter-675 (4G/5G) polymorphism 
on the plasma concentrations of PAI-1 and t-PA/
PAI-1 and bleeding volume after on-pump cardiac 
surgery.
Material and Methods
The study protocol and the informed consent 
form were approved by the Ethics Committee (No. 
151209-4L) of Pauls Stradins Clinical University 
Hospital, Riga, Latvia. Written informed consent 
was obtained from each patient.
Between May 1 and November 30, 2011, 90 adult 
patients scheduled for cardiac surgery using CPB 
were enrolled into a prospective observational study. 
For every patient, the predicted operative mortality 
was calculated using the European System for Car-
diac Operative Risk Evaluation (EuroSCORE) (19). 
The inclusion criteria were as follows: age of 
at least 18 years, first-time coronary artery bypass 
grafting (CABG) and/or valve replacement under 
CPB, EuroSCORE of <10%, values of coagulation 
tests within the reference ranges at baseline (pro-
thrombin time [PT], 70%–120%, or international 
normalized ratio [INR], 0.8–1.2; fibrinogen plasma 
concentration 1.5–3.5 g/L; platelet count [PLT], 
150–400×109/L; hemoglobin [Hb] concentration, 
>135 g/L for men and >120 g/L for women), and 
no anticoagulant, antiaggregant, or nonsteroidal an-
ti-inflammatory therapies for at least the last 5 days 
prior to surgery in order to disclose drug-induced 
platelet dysfunction. The last dose of low-molec-
ular-weight heparin (LMWH) was administered in 
the evening before the surgery. 
The exclusion criteria included emergency and 
redo operations, preoperative hemostatic disorders 
with a history of hemorrhagic events or coagulopa-
thy (PT below 50% or INR greater than 1.5, fibrin-
ogen plasma concentration less than 1.5 g/L, and 
PLT less than 100×109/L), and severe renal and/or 
hepatic dysfunctions. 
Perioperative Management. The same anesthetic 
protocol was used in all patients. Anesthesia was in-
duced with fentanyl (Fentanyl-Kalceks® 0.05 mg/mL, 
JSC Kalceks, Latvia), 0.2–0.3 mg midazolam (Dor-
micum®, F. Hoffman-La Roche AG, Basel, Switzer-
land), 0.1–0.3 mg/kg etomidate (etomidate injec-
tions 2 mg/mL, Sagent Agila, India), and 0.2 mg/kg 
cisatracurium (Nimbex 2 mg/mL, GlaxoSmithKline 
Manufacturing S.p.A, Italy) and maintained with 
sevoflurane (Sevoflurane Piramal, Piramal Health-
care Ltd, United Kingdom) at MAC 0.8–1.2. The 
patients did not receive antifibrinolytic drugs during 
and after the surgery. During CPB, anesthesia was 
maintained with fentanyl, propofol, and cisatracu-
rium at dosages of 0.03–0.06 μg/(kg·min), 3–5 mg/
(kg·h), and 0.1 mg/(kg·h), respectively. Before the 
beginning of CPB, heparin (Pan-Heparin Sodium®, 
Panpharma S.A./Rotexmedica Gmbh, Germany) was 
administered at a dose of 300 to 400 units/kg initially 
and 5000 to 10 000 units to achieve and maintain an 
activated coagulation time (ACT) above 480 seconds 
during CPB. 
Standard pulsatile CPB with an extracorpor-
eal circuit consisting of a polypropylene mem-
brane oxygenator (Admiral®, Eurosets TM, Italy) 
with moderate hypothermia (bladder temperature, 
34°C–35°C) in combination with hemodilution was 
used. Myocardial protection was achieved by using 
St. Thomas 4:1 cardioplegia (AlleMan®, Germany). 
Weaning off CPB after the surgical procedure was 
performed after rewarming the patient to a bladder 
temperature of at least 36°C. After separation from 
CPB, protamine (Protamin Meda®, Meda Pharma, 
Wien, Austria) at a dose of 1 mg per 100 units of 
heparin was administered initially, followed by ad-
ditional doses until ACT had returned to baseline.
Data Collection and Analysis. The following pre- 
and perioperative variables were taken into account: 
age, sex, body mass index (BMI), ejection frac-
tion (EF), type of surgery, extracorporeal circula-
tion time (min), aortic clamp and reperfusion times 
(min), and preoperative coagulation parameters 
such as Hb, PLT, PT, and fibrinogen. The follow-
ing parameters of fibrinolysis were analyzed: plasma 
concentrations of PAI-1 preoperatively and t-PA/
PAI-1 complex 24 hours after the surgery. In order 
to assess the fibrinolytic activity, D-dimer concen-
trations were determined at 3 time points: after the 
surgery on admission to the intensive care unit, and 
6 and 24 hours postoperatively.
Fibrinolysis was assessed by an enzyme-linked 
immunosorbent assay (ZYMUTEST®, HYPHEN 
BioMed, France) for the quantification of PAI-
1 (reference range, 1–25 ng/mL) and t-PA/PAI-1 
complex (reference range, <5 ng/mL). Moreover, 
the immunoturbidimetric test (D-dimer PLUS®, 
Dade Behring, Marburg, Germany) was used for the 
quantitative analyses of cross-linked fibrin degrada-
tion products (D-dimer, reference range, <300 ng/
mL).
Preoperatively, fibrinogen plasma concentra-
tion, PT, PLT, and Hb were recorded to allow the 
comparison among 3 groups of patients. Fibrinogen 
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plasma concentrations were determined as described 
by Clauss (20). Briefly, citrated plasma was brought 
to coagulation by the administration of an exces-
sive amount of thrombin (Multifibren U reagent, 
Siemens Healthcare Diagnostics, USA). The refer-
ence value is 1.8–3.5 g/L. PT was analyzed with a 
prothrombin complex assay (Lyophilized Dade® and 
Innovin® reagent, Siemens Healthcare Diagnostics, 
USA). 
All the coagulation parameters were determined 
using Sysmex® CA-1500 (Siemens Healthcare Di-
agnostics, Marburg, Germany). The Hb concentra-
tion and PLT were analyzed by a Beckman Coulter 
LH 750 hematology analyzer. The Coulter LH 750 
uses an impedance technology to measure the PLT 
count, and the hemoglobin cyanide method was 
used to measure Hb concentrations. 
Genomic DNA was extracted from whole blood 
using the standard phenol-chloroform extraction 
method. The region harboring the PAI-1 4G/5G 
polymorphism was amplified by the polymerase 
chain reaction (PCR) using sequence specific prim-
ers. The PCR products were then purified using 
Sap/Exo I (Thermo Scientific® Fermentas, Lithu-
ania) and sequenced on an Abi Prizm 3130xl genet-
ic analyzer. Sequence analysis was done using the 
Finch TV software.
A postoperative bleeding volume was recorded 
as chest tube drainage in mL at 24 hours postop-
eratively. Surgical bleeding was diagnosed at the 
time of re-exploration if one or more specific bleed-
ing sites were identified. The patients with surgical 
bleeding were excluded from the further study. 
Statistical Analysis. All statistical analysis was 
performed using the Statistical Package for the So-
cial Sciences (SPSS® 17.0, Chicago, USA). Contin-
uous variables were described as mean and standard 
deviation (SD) and categorical variables as percent-
ages (%). Statistical significance was defined as a 
P<0.05. The sample size was determined based on 
the number of cases hospitalized during the study 
period. The baseline data of the study groups were 
checked by an appropriate analytical test according 
to the data distribution. The Pearson correlation 
coefficient was calculated between fibrinolytic pa-
rameters and the volume of postoperative bleeding. 
The Mann-Whitney U test and the Kruskal-Wallis 
H test were used to compare continuous parameters 
in study groups for nonparametric variables and the 
Student t test or ANOVA for parametric variables. 
The ranges of PAI-1, complex of t-PA/PAI-1, D-
dimer, and postoperative 24-hour blood loss were 
compared between the different genotypes of the 
PAI-1 polymorphism.
Results
Clinical Course. In total, 90 consecutive adult 
cardiac surgical patients (47 men and 43 women) 
with a mean age of 66 years (SD, 10) were consid-
ered for inclusion. Seven patients (7.8%) required 
reoperation between 10 minutes and 32 hours after 
the surgery because of excessive bleeding or hemi-
pericardium, but none of them died. Moreover, 
during the reoperation, it was discovered that it was 
surgical bleeding. As shown in Table, 83 patients 
were subject to the further analysis and were classi-
fied into 3 groups according to the PAI-1 genotype: 
4G/4G group (n=21), 4G/5G group (n=42), and 
5G/5G group (n=20). As Table shows, there were 
no significant differences in the demographic char-
acteristics such as mean age, gender, BMI, and EF 
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Values are mean (SD) unless otherwise stated.
BMI, body mass index; EF, ejection fraction; CPB, cardiopulmonary bypass.
Table. Characteristics of Patients According to Plasminogen Activator Inhibitor Type-1 
Gene Promoter -675 (4G/5G) Polymorphism
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gen level) comparing the genotype groups. The only 
one significant difference was found for a mixed type 
of surgery: the 4G/5G carriers significantly more 
frequently underwent the surgery of this type that 
those with the 4G/4G or 5G/5G genotypes.
PAI-1 Polymorphism. The distribution of pa-
tients by the PAI-1 polymorphism was as follows: 21 
patients (25%) had the 4G/4G genotype, 42 (51%) 
had the 4G/5G genotype, and the 5G/5G genotype 
was found in 20 (24%) of the 83 patients studied. 
All alleles were in the Hardy-Weinberg equilibrium.
Relationship Between Genotype and Plasma Con-
centrations of PAI-1, t-PA/PAI-1 Complex. Signifi-
cant differences in the preoperative PAI-1 plasma 
concentrations were found comparing the patients’ 
groups by genotypes: the carriers of the 4G/5G and 
4G/4G genotypes had significantly higher preop-
erative PAI-1 plasma concentrations than those with 
the 5G/5G genotype (27 [SD, 13] and 24 [SD, 9.6] 
versus 17 ng/mL [SD, 10.8]; P=0.004 and P=0.04, 
respectively) (Fig. 1). A significant correlation was 
found between the preoperative PAI-1 plasma con-
centration and the postoperative 24-hour blood loss 
in the 4G/5G group (r=–0.4, P=0.01). 
The mean plasma concentrations of t-PA/PAI-1 
complex 24 hours after the surgery were as follows: 
5G/5G, 3.6±2.4 ng/mL; 4G/5G, 3.9±2.1 ng/mL; 
and 4G/4G, 3.1±1.8 ng/mL. However, there were 
no significant differences in the t-PA/PAI-1 complex 
levels comparing the genotype groups. Correlation 
analysis showed a significant relationship between 
the t-PA/PAI-1 complex level and the postopera-
tive 24-hour blood loss only in the 4G/5G carriers 
(r=–0.32, P=0.04).
Relationship Between Genotype and D-Dimer Lev-
els. The highest D-dimer levels were shown by the 
5G/5G genotype group postoperatively at all 3 time 
points after surgery: 334 [SD, 224], 371 [SD, 226], 
and 326 ng/mL [SD, 206] at 0, 6, and 24 hours, 
respectively. There were significant differences in 
the D-dimer level between the 5G/5G and 4G/4G 
groups at 6 hours (371 [SD, 226] vs. 232 ng/mL 
[SD, 185], P=0.03) and 24 hours (326 [SD, 207] vs. 
209 ng/mL [SD, 160], P=0.04) (Fig. 2).
Relationship Between Genotype and Postoperative 
24-Hour Blood Loss. As expected, there were dif-
ferences in the postoperative 24-hour blood loss 
comparing all the 3 PAI-1 genotypes. There was a 
significant difference in the blood loss volume at 24 
hours after surgery between the 5G/5G and 4G/4G 
genotypes (568 [SD, 192] vs. 432 mL [SD, 168], 
P=0.02). However, the greatest postoperative blood 
loss was shown by the 4G/5G carriers (609 mL [SD, 
321] per 24 hours), and it also reached a statisti-
cally significant difference in comparison with the 
4G/4G group (609 [SD, 321] vs. 432 mL [SD, 168], 
respectively; P=0.02). 
Discussion
The PAI-1 gene-675 (4G/5G) polymorphism 
is known to influence the plasma levels of PAI-1, 
which is considered as the main regulator of fi-
brinolysis (21–24). Much attention is given to the 
4G/4G polymorphism regarding to coronary ar-
tery disease; however, there are much fewer reports 
in the literature of the importance of the 5G/5G 
polymorphisms and their influence on the plasma 
PAI-1 and t-PA/PAI-1 complex concentrations and 
fibrinolytic activity.
The present study has revealed that the 5G/5G 
polymorphism may be associated with a lower pre-
operative plasma concentration of PAI-1, with high-
er levels of D-dimer, and greater bleeding after on-
pump cardiac surgery. These results are consistent 
with several recent investigations showing that the 
4G/5G polymorphism of the PAI-1 gene can affect 
fibrinolytic activity and can be associated with in-
creased postoperative bleeding (5, 24, 25).
Fig. 1. Preoperative concentration of plasminogen activator 
inhibitor type 1 (PAI-1) according to the PAI-1 genotype
P=0.04, 5G/5G carriers vs. 4G/4G, and 






































0 h                  6 h                  24 h
P=0.04
P=0.03
Fig. 2. D-dimer level postoperatively at 3 time points 
(0, 6, and 24 hours after surgery) according 
to the plasminogen activator inhibitor type 1 genotype
Values are means.
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Since PAI-1 is a more stable indicator of fibrinol-
ysis, which is usually present at higher concentra-
tions in comparison with t-PA, the PAI-1 level be-
fore the operation and the t-PA/PAI-1 complex level 
24 hours after surgery and their associations with the 
postoperative 24-hour blood loss were determined. 
The reaction between PAI-1 and t-PA, which usually 
results in the formation of the t-PA/PAI-1 complex, 
continues until t-PA is consumed. Thus, the com-
plex is considered an indicator of the concentration 
and function of active PAI-1 in blood (26). 
Regarding the preoperative PAI-1 plasma con-
centration, our study showed that PAI-1 levels 
differed according to the patients’ genotypes. The 
5G/5G carriers had the lowest levels of PAI-1 before 
the operation. Other recent studies have also ob-
served such associations between the 5G/5G geno-
type and the PAI-1 plasma concentration (22, 27). 
Burzotta et al. (24) investigated the PAI-1 4G/5G 
polymorphism association with the basal PAI-1 levels 
including 111 patients undergoing elective coronary 
bypass surgery. The PAI-1 levels were measured be-
fore surgery, daily up to 72 hours, and at discharge. 
They concluded that the PAI-1 levels were higher in 
the carriers of the 4G-allele than 5G/5G homozy-
gotes because of higher baseline values.
To the best of our knowledge, the literature is 
scanty on the reports focusing on the importance of 
the t-PA/PAI-1 complex and its relationship with 
the PAI-1 gene-675 (4G/5G) polymorphism. We 
expected to find the association between the t-PA/
PAI-1 complex level and the PAI-1 genotype as 
well because the clearance rate of the t-PA/PAI-1 
complex is slower than that of free t-PA. It follows 
consequently that the lower the plasma PAI-1 level, 
the smaller amount of the t-PA/PAI-1 complex will 
be generated in the circulation (12). Unfortunately, 
we could not find a statistically significant difference 
in the complex plasma concentrations comparing 3 
PAI-1 genotypes. Even more, the 4G/4G carriers 
demonstrated the lowest plasma concentrations of the 
t-PA/PAI-1 complex 24 hours after surgery, and the 
4G/5G carriers, the highest. We speculate that the 
values of t-PA/PAI-1 complex could be still influ-
enced by CPB as it is well known that the PAI-1 and 
t-PA/PAI-1 concentrations are increased after CPB 
as part of the “fibrinolytic shut down,” and they start 
to rise immediately after surgery and slowly decrease 
in the following days after surgery (28, 29). The car-
riers of the 4G/5G genotype showed also the high-
est preoperative plasma PAI-1 concentrations. In the 
4G/5G group, a significant correlation was found be-
tween the preoperative PAI-1 and t-PA/PAI-1 com-
plex levels at 24 hours after the surgery, and the post-
operative 24-hour blood loss. We propose that the 
lack of such a correlation could be explained by the 
fact that the 4G/5G genotype group was the biggest 
as to the patients’ sample size. Other researchers also 
observed associations between the PAI-1 level and 
the postoperative bleeding volume (5, 25). 
The PAI-1-675 (4G/5G) gene polymorphism af-
fects the PAI-1 plasma concentration in circulation 
and therefore fibrinolytic activity, which can be con-
firmed by higher levels of D-dimer (30). In our study, 
D-dimer postoperatively reached a higher level in the 
5G/5G group in comparison with the 4G/5G and 
4G/4G genotype groups. Additionally, the 4G/5G 
and 5G/5G carriers had a greater bleeding volume 
24 hours after the surgery compared with the 4G/4G 
genotype group. It is difficult to isolate only one 
factor affecting blood loss after CPB. We speculate 
whether the greater blood loss after surgery in the 
4G/5G group could be influenced by hypothermia, 
hemodilution, and other factors, not only by the PAI-
1 genotype. Furthermore, only in the 5G/5G group 
bleeding was confirmed with the increased D-dimer 
levels postoperatively indicating enhanced fibrinoly-
sis. Our finding is consistent with the recent studies 
where an association between the PAI-1 gene 4G/5G 
polymorphism and postoperative bleeding volume 
was also found (1, 23). Jimenez Rivera et al. (5) stud-
ied genetic factors associated with excessive bleed-
ing after cardiopulmonary bypass. They performed 
a study on 26 patients. Excessive bleeding was ob-
served in 1 (20%) of the 5 4G/4G genotype carriers, 
5 (42%) of the 12 4G/5G carriers, and 7 (78%) of 
the 9 5G/5G carriers. They concluded that excessive 
bleeding was significantly associated with the 5G ho-
mozygote for the PAI-1 polymorphism. 
The following limitations should be acknowl-
edged. The main limitation is a relatively low sample 
size because of financial limitations for the determi-
nation of the PAI-1 gene polymorphism and DNA 
extraction as well as for the determination of a fi-
brinolytic marker. It also would be advantageous to 
determine preoperatively the t-PA and PAI-1 plasma 
concentrations separately and simultaneously with 
the t-PA/PAI-1 complex concentrations 24 hours 
after the surgery. This would allow us to better un-
derstand the relationship between free t-PA, free 
PAI-1 antigen, and their complexes as the t-PA/PAI-
1 complex. Although the sample size is the main 
limitation of this study, the association of the PAI-1 
gene-675 (4G/5G) polymorphism with the plasma 
levels of PAI-1 and D-dimer, and postoperative 24-
hour blood loss of patients after cardiac surgery em-
ploying cardiopulmonary bypass was assessed.
Conclusions
Associations between the PAI-1 promoter-675 
(4G/5G) polymorphism, preoperative PAI-1 plasma 
concentrations, and postoperative 24-hour blood 
loss were observed. The carriers of the 5G/5G gen-
otype showed the lower preoperative PAI-1 levels, 
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greater tendency to chest tube blood loss, and high-
er D-dimer levels after cardiac surgery employing 
cardiopulmonary bypass indicating that the 5G/5G 
carriers may have an enhanced fibrinolytic activity.
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